These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26085073)

  • 21. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?
    Fautrel B; Den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):550-65. PubMed ID: 26697766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose down-titration of biological disease-modifying antirheumatic drugs in daily clinical practice: Shared decision-making and patient treatment preferences in Japanese patients with rheumatoid arthritis.
    Komiya T; Takase-Minegishi K; Sakurai N; Nagai H; Hamada N; Soejima Y; Sugiyama Y; Tsuchida N; Kunishita Y; Kishimoto D; Kobayashi K; Kamiyama R; Yoshimi R; Kirino Y; Ohno S; Nakajima H
    Int J Rheum Dis; 2019 Nov; 22(11):2009-2016. PubMed ID: 31515933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.
    Fautrel B
    Joint Bone Spine; 2018 Dec; 85(6):679-685. PubMed ID: 29452300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive therapy and remissions in rheumatoid arthritis: a systematic review.
    Hughes CD; Scott DL; Ibrahim F;
    BMC Musculoskelet Disord; 2018 Oct; 19(1):389. PubMed ID: 30376836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discontinuation of biologics in patients with rheumatoid arthritis.
    Tanaka Y; Hirata S; Saleem B; Emery P
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S22-7. PubMed ID: 24129132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Innovative strategies for treatment of rheumatoid arthritis].
    Krüger K
    Z Rheumatol; 2022 Mar; 81(2):118-124. PubMed ID: 34997270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella AC; O'Dell JR
    Curr Opin Rheumatol; 2003 May; 15(3):185-92. PubMed ID: 12707569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?
    Atzeni F; Benucci M; Talotta R; Masala IF; Sarzi-Puttini P; Govoni M
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1403-1411. PubMed ID: 27634311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA.
    den Broeder AA; van der Maas A; van den Bemt BJ
    Rheumatology (Oxford); 2010 Oct; 49(10):1801-3. PubMed ID: 20332095
    [No Abstract]   [Full Text] [Related]  

  • 34. [New options for the practice : Update S1/S2 guidelines on rheumatoid arthritis?].
    Schneider M
    Z Rheumatol; 2017 Mar; 76(2):125-132. PubMed ID: 28102443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
    Cohen SB; Cohen MD; Cush JJ; Fleischmann RM; Mease PJ; Schiff MH; Simon LS; Weaver AL
    J Rheumatol Suppl; 2008 Feb; 81():4-30; quiz 31-4. PubMed ID: 19193621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug therapy of rheumatoid arthritis].
    Arndt U; Rittmeister M; Möller B
    Orthopade; 2003 Dec; 32(12):1095-103. PubMed ID: 14655006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study.
    Yabe Y; Kojima T; Kaneko A; Asai N; Kobayakawa T; Ishiguro N
    Mod Rheumatol; 2013 Mar; 23(2):245-53. PubMed ID: 22526833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.